Immunohistochemistry CD1a Test: Advanced Cancer Detection and Diagnosis

Comprehensive Introduction to CD1a Immunohistochemistry Testing

The Immunohistochemistry CD1a Test represents a cutting-edge diagnostic approach in modern pathology and oncology. This specialized laboratory procedure utilizes advanced immunohistochemical staining techniques to detect the presence of CD1a glycoprotein markers within tissue samples. CD1a is a cell surface antigen primarily expressed on Langerhans cells, which are specialized dendritic cells found in the skin and mucosal tissues. The identification of this specific marker plays a crucial role in diagnosing various hematolymphoid malignancies and histiocytic disorders, providing clinicians with essential information for accurate disease classification and treatment planning.

What the Immunohistochemistry CD1a Test Measures and Detects

This sophisticated diagnostic test specifically targets and identifies the CD1a antigen through precise antibody binding techniques. The test measures:

• Presence and distribution of CD1a-positive cells in tissue specimens
• Intensity of CD1a staining patterns within cellular structures
• Spatial localization of CD1a expression in relation to tumor architecture
• Quantitative assessment of CD1a-positive cell populations

The detection of CD1a expression is particularly significant because this antigen serves as a reliable marker for Langerhans cells and their neoplastic counterparts. When CD1a staining is positive in abnormal tissue samples, it strongly supports diagnoses such as Langerhans cell histiocytosis, dendritic cell tumors, and certain types of T-cell lymphomas.

Who Should Consider the CD1a Immunohistochemistry Test

This specialized diagnostic test is recommended for patients presenting with specific clinical scenarios and symptoms, including:

• Patients with suspected Langerhans cell histiocytosis based on clinical findings
• Individuals with skin lesions, bone lesions, or multisystem involvement of unknown etiology
• Patients with abnormal lymph node biopsies requiring further characterization
• Cases where conventional histopathology reveals atypical dendritic cell proliferations
• Individuals with recurrent or persistent skin rashes unresponsive to standard treatments
• Patients with systemic symptoms including fever, weight loss, and organ dysfunction
• Children or adults with diabetes insipidus of unknown cause
• Cases where differential diagnosis includes histiocytic disorders versus other malignancies

Significant Benefits of CD1a Immunohistochemistry Testing

Choosing the Immunohistochemistry CD1a Test provides numerous advantages for both patients and healthcare providers:

• Accurate Diagnosis: Provides definitive identification of Langerhans cell histiocytosis and related disorders
• Treatment Guidance: Helps oncologists develop targeted treatment strategies based on precise disease classification
• Prognostic Information: Offers valuable insights into disease behavior and potential clinical outcomes
• Differential Diagnosis: Distinguishes between various histiocytic disorders and other similar conditions
• Minimally Invasive: Utilizes existing tissue samples without requiring additional invasive procedures
• Rapid Results: Provides diagnostic clarity within 5-7 days for timely treatment initiation
• Cost-Effective: Advanced diagnostic testing at an affordable $76 USD price point

Understanding Your CD1a Test Results

Interpreting CD1a immunohistochemistry results requires professional medical expertise, but general guidance includes:

• Positive Result: Indicates the presence of CD1a-positive cells, strongly supporting diagnoses like Langerhans cell histiocytosis or dendritic cell tumors. Your healthcare provider will correlate these findings with clinical presentation and other diagnostic tests.
• Negative Result: Suggests the absence of CD1a expression in the tested tissue, which may help exclude certain histiocytic disorders from consideration.
• Focal Positivity: Limited CD1a staining may indicate specific subtypes or require additional testing for comprehensive evaluation.
• Interpretation Context: Results are always interpreted in conjunction with clinical history, physical examination findings, and other laboratory tests.

It’s essential to discuss your specific results with your oncologist or pathologist, who can provide personalized interpretation and recommend appropriate next steps based on your unique medical situation.

Test Pricing and Availability

Nationwide Testing Availability

GGC DNA provides comprehensive Immunohistochemistry CD1a testing services across the United States. We have established branches in all major metropolitan areas including New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, San Jose, and many other cities. Our nationwide network ensures that patients receive consistent, high-quality diagnostic services regardless of location.

Sample Requirements and Turnaround Time

For optimal testing accuracy, please ensure proper sample collection and submission:

• Sample Type: Submit tumor tissue in 10% formal-saline OR formalin-fixed paraffin-embedded block
• Shipping: Ship samples at room temperature with appropriate packaging
• Required Documentation: Provide a copy of the histopathology report, site of biopsy, and complete clinical history
• Turnaround Time: Samples accepted daily by 6 PM; Reports available: Block – 5 days, Tissue Biopsy – 5 days, Tissue large complex – 7 days

Take Action for Your Health Today

Don’t let diagnostic uncertainty delay your treatment journey. The Immunohistochemistry CD1a Test provides the clarity needed for accurate diagnosis and effective treatment planning. Our team of experienced pathologists and oncology specialists is ready to assist you with comprehensive testing and expert interpretation.

Book your Immunohistochemistry CD1a Test today by calling +1(267) 388-9828 or visiting your nearest GGC DNA location. Take the first step toward definitive diagnosis and personalized treatment with our advanced cancer detection services.